Search
Sorafenib i lenvatinib per al tractament en primera línia del carcinoma hepatocel·lular (CHC)
(2020-07-29)
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, the fifth most common cancer in men and the seventh in women, and is associated with high mortality, which is the third leading cause of cancer death. ...
Patiròmer i ciclosilicat de sodi i zirconi per al tractament de la hiperpotassèmia
(2021-05-06)
Serum potassium levels (K-S) are normally maintained within narrow limits (3.5-5.0 mmol / L) by multiple mechanisms. Such strict regulation is essential for numerous cellular processes. Imbalances in potassium (K) homeostasis ...
Atezolizumab per al tractament del carcinoma urotelial localment avançat o metastàtic
(2018-10-18)
Urothelial carcinoma (CU) of urinary tract, also known as cell carcinoma transitional of the urinary tract, represents around 85-95% of all the cancers of the urinary tract. The term urothelial refers to the epithelium ...
Brentuximab vedotina per al tractament de la malaltia de Hodgkin: informe d'avaulació de resultats
(2018)
Lymphoma or Hodgkin's disease is a neoplasm that affects the lymphatic tissue. Symptomatology includes the growth of lymph nodes, spleen and other immune tissues, as well as fever, weight loss, fatigue, night sweats and ...
Burosumab per al tractament de la hipofosfatèmia congènita
(2021-01-21)
X-linked hypophosphatemia (HLX) is a dominant, chronic, and debilitating inherited disease caused by inactivating mutations in the PHEX gene (Phosphate-regulating gene with homologies to endopeptidases on the X chromosome). ...
Pertuzumab en combinació amb trastuzumab i quimioteràpia per al tractament neoadjuvant de pacients adults amb càncer de mama HER2 positiu, localment avançat, inflamatori, o en estadi precoç amb alt risc de recaiguda: informe d'avaluació de resultats
(2020)
Breast cancer (BC) is the most common neoplasm in women and the leading cause of cancer death in European women. Pertuzumab is a monoclonal antibody that inhibits epidermal growth factor (HER2) receptor 2 dimerization. The ...